about
Short-term digestive tolerance of chocolate formulated with maltitol in children.Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.Association Between Hypoglycemia and the Burden of Comorbidities in Hospitalized Vulnerable Older Diabetic Patients: A Cross-Sectional, Population-Based Study.Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstructionPrevalence of hypobetalipoproteinemia and related psychiatric characteristics in a psychiatric population: results from the retrospective HYPOPSY StudyPCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's DiseaseOne-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromesCirculating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective studyCirculating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk populationFatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB studyPhenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
P50
Q33446404-1090175E-D945-49D2-962E-80810256B8B9Q36506609-20643DD7-65BE-477D-9CF9-4664EDB54D36Q37397710-175F231A-669F-4AE4-BF8D-B0214FD1A629Q38845751-52D00656-1CE9-48A4-BFF7-5AE863B0D859Q46558443-98641DF4-8A95-4F17-855D-C3C39A21544AQ51349865-37715983-FB42-4035-9F35-10AAF07940BEQ51769247-F1673B32-DD0C-46EB-8DB2-EAA7D39690E3Q57821882-1229408D-7B71-49E2-8926-E3635EA69CD1Q58607937-274DDCA2-3241-4192-B1E4-171C1523925DQ88121151-DA579B62-18A0-4842-AB45-650190365E43Q88462049-699E9091-7F7F-47CC-A2D4-C3F4D343D03DQ88899892-3A14B119-761F-44EC-A914-0CAE22745F2EQ91814141-F4303EB2-8368-4D25-9CF0-3CA7BF80B32DQ92982263-51E554BC-F531-4BB2-A7B4-8348ACE76D4BQ96023320-F1C46D1D-872C-4F06-811B-D0F79EFAD08C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Matthieu Pichelin
@en
Matthieu Pichelin
@nl
type
label
Matthieu Pichelin
@en
Matthieu Pichelin
@nl
prefLabel
Matthieu Pichelin
@en
Matthieu Pichelin
@nl
P108
P31
P496
0000-0002-6822-6132